FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors

Alberto Servetto, Luigi Formisano, Carlos L. Arteaga

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Fibroblast growth factors (FGFs) and their receptors (FGFRs) have been extensively investigated in solid malignancies, representing an attractive therapeutic target. In breast cancer, especially in estrogen receptor positive (ER+) subtype, FGFR signaling aberrations have been reported to contribute to proliferation, dedifferentiation, metastasis and drug resistance. However, clinical trials evaluating the use of FGFR inhibitors in breast cancer have had disappointing results. The different biological properties of distinct FGFR alterations and lack of established patient selection criteria, in addition to the early use of non-selective inhibitors, are possible reasons of this failure. Herein, we review the current knowledge regarding the role of FGFR signaling in endocrine resistance in breast cancer. We will also summarize the results from the clinical development of FGFR inhibitors in breast cancer, discussing future challenges to identify the correct cohorts of patients to enroll in trials testing FGFR inhibitors.

Original languageEnglish (US)
Article number188595
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1876
Issue number2
DOIs
StatePublished - Dec 2021

Keywords

  • Breast cancer
  • Endocrine resistance
  • FGFR1
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors'. Together they form a unique fingerprint.

Cite this